Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
7.7(c) 7.08(c) 6.94(c) 6.82(c) 6.805 Last
15 718 792 11 992 114 10 251 547 11 000 366 4 299 347 Volume
+3.77% -8.05% -1.98% -1.73% -0.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -25,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -56,8x
Yield 2021 -
Sales 2022 136 M - -
Net income 2022 118 M - -
Net Debt 2022 - - -
P/E ratio 2022 12,6x
Yield 2022 -
Capitalization 1 352 M 1 352 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 9,96x
Nbr of Employees 15
Free-Float 97,5%
More Financials
Company
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy... 
More about the company
Ratings of Ocugen, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about OCUGEN, INC.
07/26OCGN INVESTOR NOTICE : ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. ..
PR
07/23DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
07/21OCUGEN : Levi & Korsinsky, LLP
AQ
07/20OCUGEN : The Law Offices of Frank R. Cruz Announces the Filing of a Securities C..
PR
07/20OCUGEN, INC. : Other Events (form 8-K)
AQ
07/19VIRGIN GALACTIC : The Law Offices of Vincent Wong
AQ
07/16OCUGEN : Pomerantz Law Firm Announces the Filing of a Class Action Against Ocuge..
PR
07/16OCUGEN INC : .áAnnounces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
07/15OCUGEN : Announces Initiation of Rolling Submission to Health Canada for COVAXIN..
PU
07/15OCUGEN, INC. : Other Events (form 8-K)
AQ
07/15Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for ..
CI
07/15OCUGEN : Starts Rolling Submission in Canada of COVID-19 Vaccine
MT
07/15OCUGEN : áAnnounces Initiation of Rolling Submission to Health Canada for COVAXI..
AQ
07/15Ocugen, Inc.áAnnounces Initiation of Rolling Submission to Health Canada for ..
CI
07/14OCGN INVESTOR ALERT : Investors With Substantial Losses Have Opportunity to Lead..
BU
More news
News in other languages on OCUGEN, INC.
07/15Ocugen, Inc. annonce le lancement d'une présentation en continu à Santé Canad..
05/06UN begrüßen US-Vorstoß zu Patentschutzes bei Corona-Impfstoffen
05/06CORONA-IMPFSTOFFE : Afrika setzt auf Unterstützer des US-Vorstoßes
05/06AKTIEN IM FOKUS 3 : Curevac und Biontech brechen ein - Droht Patentaussetzung?
05/06AKTIEN IM FOKUS 2 : Curevac und Biontech brechen ein - USA für Patentaussetzung
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 6,82 $
Average target price 7,90 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.272.68%1 352
MODERNA, INC.221.50%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.38.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-18.34%28 525